Direkt zum Inhalt
Merck

Prevention of tumors of the large intestine by celecoxib in mice.

In vivo (Athens, Greece) (2005-07-08)
Melissa Coles, Bela Toth
ZUSAMMENFASSUNG

Celecoxib (C), a COX-2 enzyme inhibitor, was administered at a 0.1% dose level in the diet of female Swiss Webster CFW outbred mice for life. The mice also received 1,2-dimethylhydrazine dihydrochloride (1,2-DMH) as 10 weekly subcutaneous injections at 20 microg/g body weight. The number of animals with large intestinal cancer and the total number of these cancers were 30 and 321 in the 1,2-DMH-treated group, while the corresponding figures in the C and 1,2-DMH-treated group were 29 and 156. This difference is statistically highly significant. The literature contains a limited number of publications concerning the cancer chemopreventive activity of C, particularly in mice. The present work, thus, provides additional proof in this field of interest.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
1,2-Dimethylimidazol, 97%